A Dual Inhibitor of Cdc7/Cdk9 Potently Suppresses T Cell Activation

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

(2019) Elijah W. Chen et al.   Jove-Journal of Visualized Experiments

Development of Chemotherapy with Cell-Cycle Inhibitors for Adult and Pediatric Cancer Therapy

(2018) Christopher C. Mills et al.   CANCER RESEARCH

Development of a screening strategy for new modulators of T cell receptor signaling and T cell activation

(2018) Elijah W. Chen et al.   Scientific Reports

Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer

(2018) Hanghang Zhang et al.   CELL

Inhibitors of cyclin-dependent kinases as cancer therapeutics

(2017) Steven R. Whittaker et al.   PHARMACOLOGY & THERAPEUTICS

CDK9-dependent RNA polymerase II pausing controls transcription initiation

(2017) Saskia Gressel et al.   eLife

Overview of CDK9 as a target in cancer research

(2016) Fatima Morales et al.   CELL CYCLE

Targeting WEE1 Kinase in Cancer

(2016) Christopher J. Matheson et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Aurora A drives early signalling and vesicle dynamics during T-cell activation

(2016) Noelia Blas-Rus et al.   Nature Communications

Cyclin dependent kinase (CDK) inhibitors as anticancer drugs

(2015) Concepción Sánchez-Martínez et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Cdc7 overexpression is an independent prognostic marker and a potential therapeutic target in colorectal cancer

(2015) Nathaniel Melling et al.   Diagnostic Pathology

Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment

(2015) Xiaoqi Liu   Translational Oncology

Aurora Kinase Inhibitors: Current Status and Outlook

(2015) Vassilios Bavetsias et al.   Frontiers in Oncology

Cdc7-Dbf4 Kinase Overexpression in Multiple Cancers and Tumor Cell Lines Is Correlated with p53 Inactivation

(2015) Dorine Bonte et al.   NEOPLASIA

Serine-threonine kinases in TCR signaling

(2014) María N Navarro et al.   NATURE IMMUNOLOGY

The Potent Cdc7-Dbf4 (DDK) Kinase Inhibitor XL413 Has Limited Activity in Many Cancer Cell Lines and Discovery of Potential New DDK Inhibitor Scaffolds

(2014) Nanda Kumar Sasi et al.   PLoS One

Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor

(2013) T K Albert et al.   BRITISH JOURNAL OF PHARMACOLOGY

Increased Cdc7 expression is a marker of oral squamous cell carcinoma and overexpression of Cdc7 contributes to the resistance to DNA-damaging agents

(2013) An Ning Cheng et al.   CANCER LETTERS

Cdc7-dependent and -independent phosphorylation of Claspin in the induction of the DNA replication checkpoint

(2013) Michael Rainey et al.   CELL CYCLE

Coreceptor affinity for MHC defines peptide specificity requirements for TCR interaction with coagonist peptide–MHC

(2013) John A.H. Hoerter et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Flow Cytometric Quantification of All Phases of the Cell Cycle and Apoptosis in a Two-Color Fluorescence Plot

(2013) Christine Vignon et al.   PLoS One

A new look at T cell receptor signaling to nuclear factor-κB

(2013) Suman Paul et al.   TRENDS IN IMMUNOLOGY

Discovery of XL413, a potent and selective CDC7 inhibitor

(2012) Elena S. Koltun et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Negative Selection Assay Based on Stimulation of T Cell Receptor Transgenic Thymocytes with Peptide-MHC Tetramers

(2012) Vasily Rybakin et al.   PLoS One

Dbf4 Is Direct Downstream Target of Ataxia Telangiectasia Mutated (ATM) and Ataxia Telangiectasia and Rad3-related (ATR) Protein to Regulate Intra-S-phase Checkpoint

(2011) Alan Yueh-Luen Lee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Mechanisms of Action of a Dual Cdc7/Cdk9 Kinase Inhibitor against Quiescent and Proliferating CLL Cells

(2011) A. Natoni et al.   MOLECULAR CANCER THERAPEUTICS

Hsk1- and SCFPof3-Dependent Proteolysis of S. pombe Ams2 Ensures Histone Homeostasis and Centromere Function

(2010) Yuko Takayama et al.   DEVELOPMENTAL CELL

How do Cdc7 and cyclin-dependent kinases trigger the initiation of chromosome replication in eukaryotic cells?

(2010) K. Labib   GENES & DEVELOPMENT

T Cell Receptor (TCR)-induced Tyrosine Phosphorylation Dynamics Identifies THEMIS as a New TCR Signalosome Component

(2010) Claudia Brockmeyer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phthalazinone Pyrazoles as Potent, Selective, and Orally Bioavailable Inhibitors of Aurora-A Kinase

(2010) Michael E. Prime et al.   JOURNAL OF MEDICINAL CHEMISTRY

Deciphering Protein Kinase Specificity Through Large-Scale Analysis of Yeast Phosphorylation Site Motifs

(2010) J. Mok et al.   Science Signaling

SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples

(2009) Andrew Conroy et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Meiosis: DDK Is Not Just for Replication

(2009) Adele L. Marston   CURRENT BIOLOGY

Overexpression of cell division cycle 7 homolog is associated with gene amplification frequency in breast cancer

(2009) Matthias Choschzick et al.   HUMAN PATHOLOGY

The role of the Saccharomyces cerevisiae Cdc7–Dbf4 complex in the replication checkpoint

(2008) Hiroo Ogi et al.   GENE

First Cdc7 Kinase Inhibitors: Pyrrolopyridinones as Potent and Orally Active Antitumor Agents. 2. Lead Discovery†

(2008) Maria Menichincheri et al.   JOURNAL OF MEDICINAL CHEMISTRY

A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity

(2008) Alessia Montagnoli et al.   Nature Chemical Biology